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ABSTRACT
In wound care research, available high-level evidence according to the evidence
pyramid is rare, and is threatened by a poor study design and reporting. Without
comprehensive and transparent reporting, readers will not be able to assess the
strengths and limitations of the research performed. Randomized clinical trials
(RCTs) are universally acknowledged as the study design of choice for comparing
treatment effects. To give high-level evidence the appreciation it deserves in wound
care, we propose a step-by-step reporting standard for comprehensive and transparent
reporting of RCTs in wound care. Critical reporting issues (e.g., wound care termi-
nology, blinding, predefined outcome measures, and a priori sample size calculation)
and wound-specific barriers (e.g., large diversity of etiologies and comorbidities of
patients with wounds) that may prevent uniform implementation of reporting stan-
dards in wound care research are addressed in this article. The proposed reporting
standards can be used as guidance for authors who write their RCT, as well as for peer
reviewers of journals. Endorsement and application of these reporting standards may
help achieve a higher standard of evidence and allow meta-analysis of reported
wound care data. The ultimate goal is to help wound care professionals make better
decisions for their patients in clinical practice.
In the present era of evidence-based medicine, the use of best
available evidence has become an essential part of clinical
decision making to ensure and improve quality of care. The
requirements to meet this hunger for evidence are the follow-
ing: first, a proper design and conduct of studies rendering
convincing evidence, and second a clear and concise, but at
the same time comprehensive and unbiased, description of the
conducted research to show the validity of the study and the
effect of the intervention investigated.
In wound care research, available high-level evidence
according to the evidence pyramid1 is rare, and is threatened
by either a poor study design or inconclusive results.2–6
Nevertheless, the number of scientific publications in wound
care shows a 30-fold increase over the last five decades.7
During this period, numerous guidelines and recommenda-
tions have been developed to improve the quality of design
and conduct of wound care research.3,5,8
Unfortunately, upgrading the quality of a study design does
not automatically improve the quality of reporting in wound
care publications.4,9–11 First, positive study results tend to be
published more often than indifferent or negative study
results, known as publication bias. Second, adverse events
may be neglected or reported selectively (also known as
reporting bias, caused by the researchers). Third, the nomen-
clature of essential terms or presentation of the results may
differ from other publications in similar areas.6,12–15 These
sources of bias emphasize the need for full and transparent
reporting of wound care research, which will allow readers to
assess the strengths and limitations of the research performed,
and may also protect clinicians from integrating biased results
in their clinical decision making.12
Besides improving the quality of a study design, the
(updated) Consolidated Standards of Reporting Trials
(CONSORT) statement has been published with the goal of
improving the reporting standards of randomized clinical
trials (RCT).16 Many scientific journals have endorsed this
statement or have incorporated it in their instructions for
authors.17 Even though these recommendations have had a
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positive effect on the quality of reporting standards,18 huge
variation exists in terms of implementation.19,20 Wound-
specific barriers (e.g., variety of etiologies and multiple
factors influencing wound healing) and the lack of specifica-
tion in the CONSORT statement for wound care may prevent
the uniform implementation of reporting standards in wound
care research.21
Despite international recognition of RCTs as the putative
“gold standard” for effectiveness,3,22,23 this design is relatively
seldom used for wound care treatments.2–4,24–26 Specific barri-
ers to perform RCTs in the realm of wound care27,28 include
the large diversity of etiologies and comorbidities, the
plethora of treatment options, and invalid or unreliable assess-
ment of outcome measures, which hamper adequate perfor-
mance and reporting of RCTs. This often leads to the
unsatisfying conclusion that “there is a need for large, high-
quality RCTs in wound care.”29–31
To give high-level evidence the appreciation it deserves in
wound care, we propose a step-by-step standard for compre-
hensive and transparent reporting of RCTs in wound care.
These recommendations may result in uniformity of publica-
tion output, allow a meta-analysis of reported wound care
data, and thus contribute to the potential for improving the
quality of wound care delivery.
REPORTING STANDARDS
Title and abstract
The title should point out the major aim, result, or finding of
your study.32 The revised CONSORT statement requires iden-
tification of the study design in the title.16 A carefully chosen
title, keywords (if required), and a well-structured abstract
helps in indexing your publication for easy retrieval as an
RCT. At the end of the abstract, the trial registration number
should be stated, as well as the database in which it is regis-
tered, for reasons given in the methods section. Common
databases include http://www.controlled-trials.com, http://
www.icmje.org, http://www.clinicaltrials.gov, and http://
www.trialregister.nl.
Introduction
The introduction compactly defines the problem (i.e., the area
of uncertainty) and its importance in general, and identifies
what is known about the topic in the literature and what is yet
unknown. This illustrates the importance of performing this
particular wound care study.33,34
In the first part, summarize, refer, and elaborate on the
scientific background related to your research question. A
convincing identification of the key issues in current literature
is required to set the scene for your trial.33,35 In wound care,
prevalence numbers of wounds or systematic (meta-)reviews
regarding intervention are often limited. Nevertheless, strive
to summarize the best available and up-to-date evidence, or
refer to national databases to sketch the size of the wound-
related problem, including the overall impact on health and
social gain.
Furthermore, state the benefits of study completion. For
this article, we state that the gain of reporting standards will
be “uniformity of publication output and allowing meta-
analysis of reported wound care in the future.” You may want
to use “what (will happen) if we have the results” scenarios to
formulate these perspectives.
The last paragraph of the introduction section states the aim
of the study, the rationale, the specific objectives, and the
hypothesis or purpose. For example, “aging populations
living with chronic wounds,” “variation in wound care,” or
“innovative wound materials launched on the market without
sufficient evidence for effectiveness” could motivate the ini-
tiative or perspective of the study. The aim of the study should
preferably be formulated along the PICO acronym,36 describ-
ing the Patient’s problem, the Intervention under study, the
Comparator or standard intervention, and the Outcome
parameter(s) of interest.
Methods
In general, describe how you performed your RCT in such a
way that any research-oriented reader could evaluate and
repeat your work.
The method section is pivotal for the reader to appreciate
the validity of a trial and to facilitate the choice for further
reading. Assist your reader in interpreting the quality of the
trial (“did you do the best you could?”) and the possible
sources of risk of bias (“does the reader believe your
results?”), as high-level research methods do not preclude
important risks of bias.37 Wound care research is sensitive to
some particular forms of bias, which may have serious impact
on the reliability and generalizability of the results. For
example, an adequate and concealed randomization proce-
dure, clear eligibility criteria, a priori sample size calculation
and the powering of the study, intention-to-treat analysis,
blinding of at least the outcome assessor, and duration and
completeness of follow-up are regularly underreported or
even overlooked, which may cause justified suspicion of
bias.6
In wound care, terminology is known to vary among
nations, disciplines, and caregivers.3 Therefore, state or
describe your definitions clearly, especially when confusing
terminology exists, e.g., wound etiology, regarding debride-
ment, measurement of wound healing, or categories of wound
dressing materials.
To assist readers in judging your results and any potential
sources of bias, report the following criteria, which are essen-
tial in wound care.
• Clearly define your inclusion and exclusion criteria, e.g.,
etiology of the wound, wound size, internal controls
(e.g., whether two wounds are required or a single wound
is split in half to test the intervention and control treat-
ment), duration of the wound, previous treatment
received (e.g., debridement and standard treatment), and
prognostic factors that may impair wound healing (e.g.,
smoking, diabetes, obesity, weight loss, use of systemic
corticosteroids, radiation therapy). This helps the reader
judge the generalizability of your study results.
• Without a sample size calculation, the reader cannot
assess whether observed differences are meaningful and
representative of the truth in real life. When no prelimi-
nary data exist to determine your sample size, which is
often the case with prevalence of (acute) wounds or com-
plications, motivate why a certain anticipated wound
occurrence, infection rate, or pain reduction is clinically
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relevant. Small sample sizes in wound care often require
the use of restriction (to achieve balance between groups
in size or characteristics), as compared with the “simple
randomization” in larger trials. The methods used to
restrict the randomization, along with the method used
for random selection, should be specified (such as block-
ing and block sizes). If stratified randomization is
applied, report why variables are likely or known to
influence the outcome in a substantial way (e.g., ulcer
duration, wound size or center).
• In wound care, the unit of randomization might be
patients’ wounds or clusters. Report and explain why
either one is chosen as a subject of randomization. Inclu-
sion of multiple wounds per patient may introduce prob-
lems such as interdependency and overestimation of the
precision.
• Specify the method of sequence generation, such as a
random-number table or a computerized random number
generator, providing your reader sufficient information to
assess the likelihood of bias in the group assignment.
• Report how the patient allocation is concealed, e.g., by
central allocation or by sealed envelopes. This allows
the reader to judge whether enrolment of patients can
be influenced by foreknowledge of the treatment
assignment.
• Report who generated the allocation sequence, who
enrolled participants, and who assigned participants to
trial groups. Even a perfect randomization schedule can
lead to bias if implemented incorrectly.
• Many wound care products or interventions leave recog-
nizable marks (e.g., negative pressure therapy or tissue
adhesives), which makes blinding complicated. Report
attempts to solve the blinding issues, e.g., covering the
wound material with the same secondary dressings. If
blinding is not possible, the importance of using a
blinded assessment technique (as objective as possible)
becomes vital and should be reported (e.g., wound
healing was assessed by an independent caregiver who is
blind to the treatment given).
• Define the wound treatment in terms of devices, materi-
als, technology or drugs, brands, dressing change fre-
quencies, dosages, and/or sizes of the materials used. If
the interventions change during the healing process, also
document the condition of the wound or the wound-
healing phase at the time of change. Document possible
influence of the caregiver providing the intervention
(e.g., expertise, education level, or familiarity with the
wound material or device). You may want to describe
solutions to prevent expert-based bias by means of pro-
tocols (e.g., dressing instructions provided by the
manufacturer, or documentation of the wounds with
uniformly taken digital photographs). Furthermore,
co-interventions should be reported (e.g., antiseptics
used in case of local infection). Interventions like anti-
biotics, secondary dressings, or compression therapy can
especially influence the outcome of wound healing or
infection rate.
• Report how and when your outcome measures were
assessed and why they are considered as patient-relevant.
For example, (time to) complete healing seems to be
more relevant to patients than a proportion of the wound
area healed. This is especially true for acute wounds,
whereas for complex wounds the reduction of pain or
slough, or the percentage of healing, can also be consid-
ered patient-relevant.
The relation of the outcome measure to the interven-
tion needs to be explained, and why this is an objective
measure (e.g., assessment was blinded by an independent
caregiver or researcher with a validated outcome tool).
Report these outcome measurements accurately, so that
your study results are reproducible and their validity can
be judged. Important outcomes in wound care research
are wound healing, reoccurrence of wounds, number and
proportion of complications/adverse events, quality of
life, length of hospital stay, number of visits to the out-
patient (wound) clinic, and costs.38
• State the duration of the follow-up period. This is espe-
cially important for the reader to interpret outcomes,
such as wound healing, infection, scarring, or reoccur-
rence of the wound. Also, authors of systematic reviews
can only perform meta-analysis when the follow-up
periods are homogenous. To allow for this meta-analysis,
report the mean and standard deviation. However, if
your data are skewed, also present the median and
interquartile range.
For larger trials, the study design and methodology may be
published beforehand in the form of a study protocol, which
will improve the standard of wound care research39 by
enabling:
• The publication of a comprehensive study protocol with
relevant details, as in the final publication of the results
of the study space is limited and it is often not possible to
report all kinds of details;
• Researchers to obtain feedback on their study design
through peer review;
• Readers to compare what was originally intended with
what was actually done (thus preventing “data dredging”
and post hoc revisions of study aims;
• Funders and researchers to see which studies are under-
way, and hence reduce duplication of research efforts;
and
• Authors of systematic reviews to find trials (ongoing or
unpublished), which may in turn reduce distortion of the
evidence due to publication bias.
As an author you may refer to the published study protocol
for further details on the protocol. Regardless of whether a
protocol has been published, it is important to provide the
fundamental elements of the CONSORT checklist in your
manuscript to show that the conduct of the trial has been
performed according to good clinical practice rules.3,16,40
Clinical trials should be registered in an international trial
(meta-)register before they are started. State the registration
number in your manuscript,41 and preferably also in the
abstract. Formal approval by the institutional review board or
similar ethics board should be stated, or whether the study
was deemed exempt from formal approval, for example, when
subjects were studied anonymously without any intervention
that might compromise their physical or psychological integ-
rity. Furthermore, all ethical issues should be reported in order
to demonstrate good clinical practice and ensure patient
safety.
When discussing statistics, your reader should be able to
judge the validity of the findings. Only use statistics as rel-
evant to the data you have gathered, with respect to the under-
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lying assumptions governing the use of the specific statistical
test. Statistics should be used to scientifically corroborate
your conclusion rather than to “chase” a statistically signifi-
cant result. Avoid the use of statistics solely to impress your
reader, as most readers will be deterred by elaborate or com-
plicated statistical methods. Always report in advance
planned (subgroup) analyses in your method section to avoid
post hoc analyses that may have the appearance of data dredg-
ing. Explain why certain calculations were made to analyze
your data. In case of stratified randomization, an adjusted time
to event analysis needs to be reported to correct for the strati-
fication. The data and/or statistical analyses are usually pre-
sented in the last subsection, as it leads the reader to the
results section.33
Results
In general, check for internal consistency of data and results
within your manuscript, as minor differences in the data pre-
sented may be viewed unfavorably by the reviewers and
editors.42
A flowchart or diagram of study participants through each
stage is recommended.16 This is vital for patients with
difficult-to-heal wounds, who are more likely to be lost during
follow-up, and thereby increase the risk of attrition bias.
Report patient exclusion, protocol violations, losses to follow-
up, crossover patients, and dropouts for each group, and the
reasons for these occurrences (e.g., painful dressing changes,
leakage, allergic reactions to materials, (serious) adverse
events, poor compliance, logistical reasons, moved or
deceased patients). As incomplete outcome data may result in
bias, report the overall proportion of participants with missing
outcome data, reasons for missing outcome data, and the
difference in the proportion of participants with missing
outcome data, and address the problem of these in your
analysis.
State whether you performed an intention-to-treat analysis,
and whether or not patients received or completed the wound
care treatment they were allocated to. This helps the reader
judge whether those not adhering to the protocol may have
inferior outcomes.
Furthermore, precisely report the eventual duration of the
follow-up period. For example, report the range of follow-up
duration, mean follow-up period with standard deviations,
and if your data are skewed also report median values with
interquartile ranges. Avoid empty terms like “until sutures
were removed” or “until complete wound healing” without
providing the actual figures.
Given the diversity of wounds, provide the reader with a
detailed and full description of your population and setting at
baseline, including the eligibility criteria mentioned in your
method section. Important demographic characters in particu-
larly complex wound care research are age, sex, ethnics, type
of wound (in relation to etiology), duration of existence of the
wound, size and depth of wound, and concurrent illnesses.
Medications and relevant prognostic characteristics may
influence wound healing or adverse events. These demo-
graphic and prognostic factors are usually summarized for
each trial arm in the first table. Here, p-values should be
avoided because any baseline differences between the ran-
domization groups, if the randomization is applied correctly,
are due to chance. The p-value represents this possibility of
differences being due to chance, and are therefore by defini-
tion a p-value of 1.0.
Provide absolute numbers when feasible, in addition to
percentages (i.e., 30/60 [50%]) and averages (e.g., mean or
median) with their variability (standard deviation or
interquartile range). Means and standard deviations are pre-
ferred in order to perform future meta-analysis. However,
they are sensitive to outliers, and in case of skewed data a
median with accompanying interquartile range should also be
reported. If patient imbalances occur, report the post hoc
subgroup analysis for each outcome separately.
Always report predefined outcomes, benefits, and harms as
mentioned in the method section to prevent selective report-
ing. When presenting the results, illustrate the size of the
treatment effect (effect size) and the estimate of this treatment
effect (point estimate or precision). Effect size should be
presented in terms of relative risks (RR), risk difference (RD)
(also known as absolute risk reduction [ARR]/increase
[ARI]), number needed to treat (NNT) or number needed to
harm (NNH) with their precision expressed as 95% confi-
dence intervals (CI). This modern presentation of study
results helps your readers understand the clinical relevance
behind the statistical significance.
When reporting time-dependent parameters (e.g., time to
wound healing), remember that these events should be ana-
lyzed by means of survival methods (time to event) and log-
rank tests rather than by presenting averages (e.g., average
time to wound healing). Mean healing time is solely justified
if all patients stayed in and healed during the study period. To
report on wound-related harms, such as pain, infection, and
scar formation, use the time of measurement, the scale of the
tool used for assessing adverse events (e.g., validated pain
assessment scale [numeric rating scale or visual analog
scale], or scar assessment scale [e.g., Patient Observer Scar
Assessment Scale or Vancouver Scar Scale]), relevant
co-interventions (e.g., antibiotics when assessing infection),
and prevalence or background risk of the adverse event (e.g.,
wound infection usually is such a rare event that the numbers
are too low for a meaningful comparison).
Finally, it is important to disclose any financial subvention,
whether this is an unrestricted grant or sponsored. This may
reflect the degree of involvement of the sponsor in the inter-
pretation and presentation of the trial results.
Discussion
The main purpose of this section is to answer your research
question and help readers understand its consequences in
terms of its implication for practice, policy, education, or
future research.
Do not repeat all your results; instead, start the discussion
with your factual results, its interpretation, and what these
mean for clinical practice and clinical decision making. The
section provides an opportunity to give theoretical explana-
tions, to compare your results to other, similar research, to
extrapolate to other wound types, to discuss any weaknesses
in your methods or results, and to provide suggestions for
future research.
Wound care research often has to deal with limitations,
such as open studies (no blinding), small sample sizes
(power), subjective outcome measures (e.g., leakage of
wounds), presence of comorbidities (e.g., diabetes influencing
the outcomes of wound infection or wound healing), short
Reporting standards of RCTs Brölmann et al.
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Table 1. Summary of important reporting criteria
Manuscript section Issue to be described Clarification Done
Introduction PICO The aim of the study should preferably describe the Patient’s problem,
the Intervention under study, the Comparator or standard




State or describe your definitions clearly, especially when confusing
terminology exists, e.g., regarding debridement, type of wound,





Define your inclusion and exclusion criteria to help the reader judge the




State a clear definition of the patient-relevant outcomes, which are to
be measured in a valid and reliable manner. Good examples are







Specify the method of sequence generation to provide the reader with
sufficient information to assess the likelihood of bias in the group
assignment process.
Report how patient allocation was concealed, e.g., by means of central
allocation or sealed envelops. This helps the reader judge whether







Blinding is usually difficult in wound care trials. Report any blinding





Without a sample size calculation, the reader cannot assess whether
observed differences are meaningful. Therefore, motivate why your




State whether or not the patients received or completed the wound
care treatment they were allocated to. This helps the reader judge
whether those not adhering to the protocol may have worse
outcomes.
□
Follow-up duration Define the exact duration of the follow-up period. Avoid empty terms







Provide a detailed description of your population at baseline, including
wound characteristics and eligibility criteria, to illustrate which
spectrum of patients is investigated.
□
Outcomes Report on all predefined outcomes, benefits, and harms, as stated in
the methods section to prevent selective reporting. Describe the
effect size, expressed as relative risk (RR), risk difference (RD),
number needed to treat (NNT), or number needed to harm (NNH),
with its precision expressed as 95% confidence intervals.
Time-dependent parameters (e.g., time to wound healing) should be
analyzed by means of survival methods (time to event) rather than by
means of averages (e.g., mean time to wound healing).
□
Discussion Limitations Discuss study design issues like no blinding, small sample size,
subjective outcome measures, or specific patient groups investigated
(e.g., diabetics), short follow-up period, and industry sponsorship.
□
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follow-up periods, and industry sponsorship. For example,
report the possible influence of lack of blinding on the
outcome measurement.
All too often, a positive message of effectiveness is con-
veyed, whereas the benefits and relevance to patients of the
intervention should be weighed against its possible harms,
adverse effects, and costs. Also, while pragmatic wound care
studies may provide more useful information for routine
clinical interpretation (external validity or applicability),
they also introduce the possibility of bias (e.g., local differ-
ences in treatment of patients, assessment, or treatment
given are influenced by different wound care providers with
different levels of knowledge or experience regarding the
wound material).
Depending on journal style, you may conclude with per-
ceived study results and their possible implications for prac-
tice at the end of your discussion or in a new subheading
“Conclusions.” When writing your conclusions make sure
they are coherent to your study results and your discussion.
FINAL CONSIDERATIONS
In general, the first preparatory step of the writing process is
to contemplate the scope and requirements of a suitable
journal to entrust your manuscript to. The multidisciplinary
character of wound care should influence your decision about
your intended readership (e.g., doctors, nurses, educators, or
managers of wound clinics) before choosing an appropriate
journal.
Broad endorsement of reporting standards is needed to
improve the quality of evidence-based wound care. Expla-
nation and elaboration of uniform reporting standards spe-
cific to wound care will help clinical readers, reviewers, and
journal editors to interpret and critically appraise the wound
care literature. Furthermore, they help overcome the ambi-
guity between quality of reporting and the quality of the
underlying research (i.e., flaws in study design vs. poor
reporting).
Regardless of the ongoing debate regarding whether RCTs
in wound care are uniquely difficult, wound care continues to
be a substantial problem, and the need for adequate design,
conduct, and reporting of scientific research remains stand-
ing.25,27,43,44 Any (potential) flaws in the design and conduct of
RCTs in wound care should at least be appropriately
addressed and reported in detail in order to reduce confusion
regarding the inference of the research.
Table 1 summarizes some critical reporting issues based on
the step-by-step reporting standard for RCTs in wound care as
described here. This can be used as guidance for authors who
write their RCT, as well as for reviewers of journals. Endorse-
ment and application of these reporting standards may help
achieve a high standard of evidence, with the ultimate goal of
helping wound care professionals make better decisions for
their patients in clinical practice.
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